Last Price$34.91.0%
Market Cap$17.9B
LTM Research & Development Expenses (R&D)
$673.0M
YoY Growth
+0.9%
3Y CAGR
+8.0%
5Y CAGR
+2.5%
Stock quality & Intrinsic value
5/10
51.1% undervalued
Baxter International Inc. Research & Development Expenses (R&D)
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & Development Expenses (R&D) | $533.0M | $614.0M | $760.0M | $868.0M | $917.0M | $915.0M | $946.0M | $1,156.0M | $1,246.0M | $1,421.0M | $603.0M | $647.0M | $613.0M | $655.0M | $595.0M | $521.0M | $534.0M | $605.0M | $667.0M | $181.0M |
Overvalued or undervalued?
Check the intrinsic value for BAX
and see if it's the right time to invest.
Baxter International Inc. (BAX) Research & Development Expenses (R&D) comparison analysis
General
LTM Research & Development Expenses (R&D)
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Baxter International Inc.BAX
$673.0M
0.9%
8.0%
2.5%
Median Peer Set
$292.6M
3.4%
9.4%
11.2%
Becton, Dickinson and CompanyBDX
$1,243.0M
2.4%
(3.0%)
3.0%
Intuitive Surgical, Inc.ISRG
$1,145.3M
14.7%
19.5%
15.5%
Alcon Inc.ALC
$876.0M
4.4%
1.3%
6.0%
AptarGroup, Inc.ATR
$440.6M
(22.1%)
1.9%
7.4%
ResMed Inc.RMD
$318.8M
4.8%
10.2%
10.1%
Hologic, Inc.HOLX
$266.3M
(7.0%)
(2.8%)
2.1%
Masimo CorporationMASI
$222.8M
27.2%
17.5%
19.0%
The Cooper Companies, Inc.COO
$155.1M
12.9%
18.7%
12.3%
West Pharmaceutical Services, Inc.WST
$69.1M
1.0%
9.4%
12.2%
Repligen CorporationRGEN
$41.8M
(4.0%)
9.5%
19.2%
BAX key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 9,849.0 3.6% | 10,378.0 5.4% | 11,263.0 8.5% | 12,348.0 9.6% | 12,562.0 1.7% | 12,843.0 2.2% | 13,893.0 8.2% | 14,190.0 2.1% | 15,259.0 7.5% | 16,671.0 9.3% | 9,968.0 (40.2%) | 10,163.0 2.0% | 10,561.0 3.9% | 11,127.0 5.4% | 11,362.0 2.1% | 11,673.0 2.7% | 12,784.0 9.5% | 15,113.0 18.2% | 14,813.0 (2.0%) | 4,513.0 (69.5%) |
| Cost of Goods Sold (COGS) | 5,756.0 | 5,641.0 | 5,744.0 | 6,218.0 | 6,037.0 | 6,885.0 | 6,847.0 | 6,889.0 | 7,664.0 | 8,514.0 | 5,822.0 | 6,053.0 | 6,091.0 | 6,346.0 | 6,601.0 | 7,086.0 | 7,679.0 | 9,716.0 | 9,838.0 | 2,812.0 |
% margin | 4,093.0 41.6% | 4,737.0 45.6% | 5,519.0 49.0% | 6,130.0 49.6% | 6,525.0 51.9% | 5,958.0 46.4% | 7,046.0 50.7% | 7,301.0 51.5% | 7,595.0 49.8% | 8,157.0 48.9% | 4,146.0 41.6% | 4,110.0 40.4% | 4,470.0 42.3% | 4,781.0 43.0% | 4,761.0 41.9% | 4,587.0 39.3% | 5,105.0 39.9% | 5,397.0 35.7% | 4,975.0 33.6% | 1,701.0 37.7% |
| Operating Expenses | 2,563.0 | 2,896.0 | 3,281.0 | 3,566.0 | 3,648.0 | 3,822.0 | 4,100.0 | 4,480.0 | 4,927.0 | 5,450.0 | 3,697.0 | 3,386.0 | 3,212.0 | 3,182.0 | 3,885.0 | 2,971.0 | 3,395.0 | 4,528.0 | 4,585.0 | 1,384.0 |
| Research & Development Expenses (R&D) | 533.0 | 614.0 | 760.0 | 868.0 | 917.0 | 915.0 | 946.0 | 1,156.0 | 1,246.0 | 1,421.0 | 603.0 | 647.0 | 613.0 | 655.0 | 595.0 | 521.0 | 534.0 | 605.0 | 667.0 | 181.0 |
| Selling, General & Administrative Expenses (SG&A) | 2,030.0 | 2,282.0 | 2,521.0 | 2,698.0 | 2,731.0 | 2,907.0 | 3,154.0 | 3,324.0 | 3,681.0 | 4,029.0 | 3,094.0 | 2,739.0 | 2,599.0 | 2,617.0 | 3,290.0 | 2,469.0 | 2,867.0 | 3,887.0 | 3,938.0 | 1,203.0 |
% margin | 1,639.0 16.6% | 1,841.0 17.7% | 2,168.0 19.2% | 2,564.0 20.8% | 2,877.0 22.9% | 2,136.0 16.6% | 2,946.0 21.2% | 2,821.0 19.9% | 2,668.0 17.5% | 2,562.0 15.4% | 449.0 4.5% | 724.0 7.1% | 1,291.0 12.2% | 1,599.0 14.4% | 976.0 8.6% | 603.0 5.2% | 779.0 6.1% | (549.0) (3.6%) | 390.0 2.6% | (112.0) (2.5%) |
| Interest Income | 0.0 | 0.0 | 102.0 | 72.0 | 19.0 | 28.0 | 38.0 | 26.0 | 27.0 | 22.0 | 20.0 | 23.0 | 30.0 | 48.0 | 40.0 | 19.0 | 14.0 | 20.0 | 70.0 | 0.0 |
| Interest Expense | 118.0 | 101.0 | 124.0 | 148.0 | 98.0 | 87.0 | 54.0 | 87.0 | 128.0 | 145.0 | 126.0 | 66.0 | 85.0 | 45.0 | 111.0 | 134.0 | 192.0 | 395.0 | 512.0 | 13.0 |
| Pre-tax Income | 1,444.0 | 1,746.0 | 2,114.0 | 2,451.0 | 2,734.0 | 1,890.0 | 2,809.0 | 2,889.0 | 2,549.0 | 2,439.0 | 428.0 | 4,954.0 | 1,217.0 | 1,693.0 | 970.0 | 1,292.0 | 1,477.0 | (2,353.0) | (103.0) | (135.0) |
% effective tax rate | 486.0 33.7% | 348.0 19.9% | 407.0 19.3% | 437.0 17.8% | 519.0 19.0% | 463.0 24.5% | 553.0 19.7% | 563.0 19.5% | 537.0 21.1% | 493.0 20.2% | 28.0 6.5% | (12.0) (0.2%) | 493.0 40.5% | 63.0 3.7% | (41.0) (4.2%) | 182.0 14.1% | 182.0 12.3% | 68.0 (2.9%) | (34.0) 33.0% | 177.0 (131.1%) |
% margin | 956.0 9.7% | 1,396.0 13.5% | 1,707.0 15.2% | 2,014.0 16.3% | 2,205.0 17.6% | 1,420.0 11.1% | 2,224.0 16.0% | 2,326.0 16.4% | 2,012.0 13.2% | 2,497.0 15.0% | 968.0 9.7% | 4,965.0 48.9% | 717.0 6.8% | 1,624.0 14.6% | 1,001.0 8.8% | 1,102.0 9.4% | 1,284.0 10.0% | (2,421.0) (16.0%) | 2,656.0 17.9% | (312.0) (6.9%) |
| EPS | 1.54 | 2.15 | 2.65 | 3.22 | 3.63 | 2.41 | 3.91 | 4.22 | 3.70 | 4.61 | 1.78 | 9.09 | 1.11 | 3.04 | 1.97 | 2.17 | 2.56 | (4.80) | 5.25 | 0.00 |
| Diluted EPS | 1.52 | 2.13 | 2.61 | 3.16 | 3.59 | 2.39 | 3.88 | 4.18 | 3.66 | 4.56 | 1.76 | 9.01 | 1.08 | 2.97 | 1.93 | 2.13 | 2.53 | (4.80) | 5.25 | 0.00 |
% margin | 2,190.0 22.2% | 2,416.0 23.3% | 2,819.0 25.0% | 3,230.0 26.2% | 3,406.0 27.1% | 2,767.0 21.5% | 3,633.0 26.1% | 3,697.0 26.1% | 3,488.0 22.9% | 1,636.0 9.8% | 1,494.0 15.0% | 1,972.0 19.4% | 2,050.0 19.4% | 2,477.0 22.3% | 1,870.0 16.5% | 2,536.0 21.7% | 2,519.0 19.7% | (849.0) (5.6%) | 1,678.0 11.3% | (112.0) (2.5%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Baxter International Inc.'s Research & Development Expenses (R&D)?
As of today, Baxter International Inc.'s last 12-month Research & Development Expenses (R&D) is $673.0M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Baxter International Inc.'s Research & Development Expenses (R&D) growth rate?
Over the last year, Baxter International Inc.'s Research & Development Expenses (R&D) growth was 0.9%. The average annual Research & Development Expenses (R&D) growth rates for Baxter International Inc. have been 8.6% over the past three years, 2.5% over the past five years.
3) Is Baxter International Inc.'s Research & Development Expenses (R&D) growth rate Good?
Over the last year, Baxter International Inc.'s Research & Development Expenses (R&D) growth was 0.9%, which is higher than industry growth of 0.0%. It indicates that Baxter International Inc.'s Research & Development Expenses (R&D) growth is Bad.